ABOUT US

Dr Greg Szto is an experienced and forward-thinking interventional cardiologist based on Victoria’s Mornington Peninsula. With a career spanning over two decades, Dr Szto is known for his dedication to improving patient care through innovation, advanced technology, and clinical research.

As Director of Cardiology at Peninsula Private Hospital, he has played a leading role in establishing world-class cardiac services in the region. From launching coronary angioplasty programs in both the public and private hospitals, to working collaboratively to establish open-heart surgery and introduce minimally invasive valve procedures, Dr Szto has consistently delivered firsts in high quality, comprehensive heart care.

Dr Szto’s commitment to advancing patient care extends beyond the cath lab and clinical practice into innovation and biotech. He is a strong advocate for emerging therapies that address real-world barriers to care. As the Co-Founder and Chief Medical Officer of CuboPharm, he is one of the key innovators behind a groundbreaking sublingual statin delivery platform designed specifically for patients with statin intolerance. This novel approach bypasses traditional oral administration, improving tolerability and adherence. Under his clinical leadership, CuboPharm has successfully completed patient trials, demonstrating promising outcomes for individuals who previously struggled with standard cholesterol-lowering therapies.

Always looking to the future, Dr Szto is also working in partnership with Monash University on the development of a novel cardiac-related device, continuing his drive to bridge research and real-world application.

In addition to his clinical work, Dr Szto is active in global and investigator-led trials focused on heart failure, lipid management, hypertension, and acute coronary syndromes — offering patients early access to breakthrough treatments.

Tomer Madmon is a pharmaceutical executive with over 20 years of experience in product development, CMC, and commercial strategy. As Co-Founder of CuboPharm, he leads product strategy and global alliances, advancing the company’s proprietary sublingual and orally disintegrating tablet (ODT) technologies. These platforms, based on a patented cubosome-based system, are designed to improve bioavailability, patient adherence, and therapeutic outcomes.

Prior to CuboPharm, Tomer held senior leadership roles across the pharmaceutical industry, including Head of New Product Development and Validation at Aspen Pharmacare. Earlier in his career, he contributed to the development of modified-release and complex generic formulations at Teva Pharmaceuticals.

He has successfully led regulatory submissions and product launches across multiple markets, including the TGA, Medsafe, and FDA. Tomer is a named inventor on several granted patents in Australia and the United States, covering innovations in controlled-release multiparticulate systems and mucosal delivery via cubosome-based ODTs.

His combination of technical expertise and strategic leadership supports CuboPharm’s mission to bring next-generation drug delivery solutions to market through co-development, licensing, and commercial partnerships.